Physician profile
Daniel M Englert
NPI 1891094793
$73,972.16
in general payments reported to CMS, 2019-2025
24 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $33.36 · 2021: $190 · 2022: $170 · 2023: $4,970 · 2024: $32K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $3,965 · Travel and Lodging: $1,775 · Consulting Fee: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,562.00 |
| Food and Beverage | $3,965.39 |
| Travel and Lodging | $1,775.35 |
| Consulting Fee | $972.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54,692.97 | 2019-2025 | Evenity, Prolia, Prolia |
| Kyowa Kirin, INC. | $11,324.23 | 2024-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $6,029.98 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $919.37 | 2023-2025 | |
| Radius Health, INC. | $138.18 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Boston Scientific Corporation | $122.18 | 2024 | |
| Lilly USA, LLC | $90.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.80 | 2019 | |
| Abbvie INC. | $73.03 | 2021-2022 | |
| Dexcom, INC. | $60.84 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $53.61 | 2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $51.86 | 2025 | Twiist |
| Alnylam Pharmaceuticals INC. | $22.25 | 2024 | Onpattro |
| Averitas Pharma INC. | $22.09 | 2023 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.17 | 2025 | Gemtesa |
| Novo Nordisk INC | $20.57 | 2025 | Ozempic, Rybelsus |
| Adlon Therapeutics L.P. | $20.16 | 2021 | |
| Insulet Corporation | $18.43 | 2020 | |
| Medtronic, INC. | $17.79 | 2024 | Minimed 780g |
| Beta Bionics, INC. | $17.63 | 2024 | Ilet Bionic Pancreas |
| Allergan, INC. | $14.93 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.52 | 2024 | Quviviq |
| Esperion Therapeutics, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Englert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.